Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval. Thomas JW, Jamy O, Shah MV, Vachhani P, et al. Leuk Res 2022;112:106770.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Thomas JW, Jamy O, Shah MV, Vachhani P, et al. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval. Leuk Res 2022;112:106770.
PMID: 34920340